Is Bristol Myers Squibb (BMY) a risky stock?
As of July 21, 2026, Clavix grades Bristol Myers Squibb (BMY) B- for risk, a composite score of 67 out of 100 on an A+ to F scale, which puts BMY in the "solid" band. The grade is a risk read for educational purposes, not a buy or sell recommendation.
Grade as of July 21, 2026. Clavix regrades every trading day.
The five risk dimensions behind BMY's grade
Each Clavix grade is a composite of five independent reads. Higher is safer. Here is how BMY scores on each, as of July 21, 2026.
What's moving BMY's risk right now
Company-specific signals Clavix flags behind BMY's current grade, drawn from recent news and filings as of July 21, 2026.
An rating at Erste Group Bank has cut its 2027 earnings forecast for Bristol Myers Squibb, signaling concern about the drugmaker's long-term revenue, profitability, or pipeline. Lower forward estimates can weigh on the stock.
Bristol Myers Squibb has a history of topping rating earnings expectations, and its key indicators look favorable ahead of the next report. Another beat could reinforce a positive trend for the stock.
Braveheart Bio, a newly public biotech, is developing drugs for hypertrophic cardiomyopathy, a market where Bristol Myers Squibb competes. This new entrant could pressure BMY's future market share and pricing in that indication.
What a B- grade means
On the Clavix A+ to F scale, BMY's composite of 67 falls in the B band (65–79), read as "solid." The scale is fixed, so the meaning never moves.
This page is generated from Clavix's own risk model and is for educational purposes only. It is not investment advice or a recommendation to buy or sell BMY or any security. Grades are risk indicators, not predictions of return. Data may be delayed.